FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3096105852> ?p ?o ?g. }

• W3096105852 endingPage "424" @default.
• W3096105852 startingPage "417" @default.
• W3096105852 abstract "COVID-19 associated critical illness characterized by rapidly evolving acute respiratory failure (ARF) can develop, especially on the grounds of hyperinflammation. A case-series of 61 patients admitted to our intensive care unit (ICU) between August 12 and September 12, 2020 with confirmed COVID-19 pneumonia and rapidly evolving ARF requiring oxygen support therapy and/or mechanical ventilation was retrospectively analyzed. We examined whether intravenous administration of tocilizumab, a monoclonal interleukin-6 receptor antibody, was associated with improved outcome. All patients received empiric antivirals, dexamethasone 6 mg/day for 7 days, antibiotics, and prophylactic anticoagulation. Tocilizumab was administered at a dosage of 8 mg/kg [two consecutive intravenous infusions 12 h apart]. Outcome measures such as mortality on day-14, ICU length of stay, and rate of nosocomial acquired bacterial infections were also analyzed. Results: Patients were males (88.2%) aged 51 [interquartile range (IQR): 42.5–58.75)], with admission Acute Physiology and Chronic Health Evaluation (APACHE) 4 score of 53 (IQR: 37.75–72.5), and had more than one comorbidity (62.3%). On admission, twenty nine patients (47.5%) were mechanically ventilated, and thirty two patients (52.5%) were receiving oxygen therapy. No serious adverse effects due to tocilizumab therapy were recorded. However, twelve patients (19.6%) developed nosocomial acquired infections. ICU length of stay was 13 (IQR: 9–17) days, and mortality on day-14 was 24.6%. Six patients were shifted to other hospitals but were followed-up. The overall mortality on day-30 was 31.1%. Non-mechanically ventilated patients had higher survival rates compared to mechanically ventilated patients although results were not significant [hazards ratio = 2.6 (95% confidence intervals: 0.9–7.7), p = 0.08]. Tocilizumab did not affect the mortality of critically ill COVID-19 patients. Tocilizumab could be an adjunct safe therapy in rapidly evolving COVID-19 pneumonia and associated critical illness." @default.
• W3096105852 created "2020-11-09" @default.
• W3096105852 creator A5000236602 @default.
• W3096105852 creator A5000313377 @default.
• W3096105852 creator A5007130210 @default.
• W3096105852 creator A5014871389 @default.
• W3096105852 creator A5028169620 @default.
• W3096105852 creator A5032801005 @default.
• W3096105852 creator A5041650326 @default.
• W3096105852 creator A5086041840 @default.
• W3096105852 creator A5088607819 @default.
• W3096105852 creator A5090746427 @default.
• W3096105852 date "2020-12-01" @default.
• W3096105852 modified "2023-10-16" @default.
• W3096105852 title "Tocilizumab in the treatment of rapidly evolving COVID-19 pneumonia and multifaceted critical illness: A retrospective case series" @default.
• W3096105852 cites W2073060575 @default.
• W3096105852 cites W2578466913 @default.
• W3096105852 cites W2897435863 @default.
• W3096105852 cites W2903899730 @default.
• W3096105852 cites W3006961006 @default.
• W3096105852 cites W3007238890 @default.
• W3096105852 cites W3008028633 @default.
• W3096105852 cites W3008116551 @default.
• W3096105852 cites W3008827533 @default.
• W3096105852 cites W3009219040 @default.
• W3096105852 cites W3009314935 @default.
• W3096105852 cites W3009885589 @default.
• W3096105852 cites W3012421327 @default.
• W3096105852 cites W3012849736 @default.
• W3096105852 cites W3013486442 @default.
• W3096105852 cites W3013689008 @default.
• W3096105852 cites W3013816672 @default.
• W3096105852 cites W3014001472 @default.
• W3096105852 cites W3014050022 @default.
• W3096105852 cites W3014294089 @default.
• W3096105852 cites W3014333693 @default.
• W3096105852 cites W3015552915 @default.
• W3096105852 cites W3015759088 @default.
• W3096105852 cites W3015863623 @default.
• W3096105852 cites W3016263512 @default.
• W3096105852 cites W3016473145 @default.
• W3096105852 cites W3016661132 @default.
• W3096105852 cites W3016671424 @default.
• W3096105852 cites W3021915688 @default.
• W3096105852 cites W3023217380 @default.
• W3096105852 cites W3024193040 @default.
• W3096105852 cites W3025123560 @default.
• W3096105852 cites W3029415055 @default.
• W3096105852 cites W3031456278 @default.
• W3096105852 cites W3031663595 @default.
• W3096105852 cites W3032503858 @default.
• W3096105852 cites W3032677363 @default.
• W3096105852 cites W3036398841 @default.
• W3096105852 cites W3039233076 @default.
• W3096105852 cites W3043642155 @default.
• W3096105852 cites W3044335251 @default.
• W3096105852 cites W3047115247 @default.
• W3096105852 cites W3048601848 @default.
• W3096105852 cites W3080355393 @default.
• W3096105852 cites W3093604087 @default.
• W3096105852 cites W4210642183 @default.
• W3096105852 cites W4255364305 @default.
• W3096105852 cites W4292528167 @default.
• W3096105852 doi "https://doi.org/10.1016/j.amsu.2020.10.061" @default.
• W3096105852 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7642808" @default.
• W3096105852 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33169088" @default.
• W3096105852 hasPublicationYear "2020" @default.
• W3096105852 type Work @default.
• W3096105852 sameAs 3096105852 @default.
• W3096105852 citedByCount "20" @default.
• W3096105852 countsByYear W30961058522021 @default.
• W3096105852 countsByYear W30961058522022 @default.
• W3096105852 countsByYear W30961058522023 @default.
• W3096105852 crossrefType "journal-article" @default.
• W3096105852 hasAuthorship W3096105852A5000236602 @default.
• W3096105852 hasAuthorship W3096105852A5000313377 @default.
• W3096105852 hasAuthorship W3096105852A5007130210 @default.
• W3096105852 hasAuthorship W3096105852A5014871389 @default.
• W3096105852 hasAuthorship W3096105852A5028169620 @default.
• W3096105852 hasAuthorship W3096105852A5032801005 @default.
• W3096105852 hasAuthorship W3096105852A5041650326 @default.
• W3096105852 hasAuthorship W3096105852A5086041840 @default.
• W3096105852 hasAuthorship W3096105852A5088607819 @default.
• W3096105852 hasAuthorship W3096105852A5090746427 @default.
• W3096105852 hasBestOaLocation W30961058521 @default.
• W3096105852 hasConcept C119060515 @default.
• W3096105852 hasConcept C126322002 @default.
• W3096105852 hasConcept C167135981 @default.
• W3096105852 hasConcept C179755657 @default.
• W3096105852 hasConcept C197934379 @default.
• W3096105852 hasConcept C2776376669 @default.
• W3096105852 hasConcept C2777080012 @default.
• W3096105852 hasConcept C2777178219 @default.
• W3096105852 hasConcept C2777371824 @default.
• W3096105852 hasConcept C2777575956 @default.
• W3096105852 hasConcept C2777914695 @default.
• W3096105852 hasConcept C2780347030 @default.
• W3096105852 hasConcept C2780630273 @default.

• next